Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Brief Report
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Oncology
Vol. 3, Issue 2, 2016
October 21, 2015 EDT
Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
Gabriel Tremblay
,
Unnati Majethia
,
Ilias Kontoudis
,
Jesús De Rosendo
,
spain
cost-utility
cost-effectiveness
eribulin
her2-negative
metastatic breast cancer
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9834
Photo by
Ken Treloar
on
Unsplash
JHEOR
1.
Tremblay G, Majethia U, Kontoudis I, De Rosendo J. Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy.
JHEOR
. 2015;3(2):180-193.
doi:10.36469/9834
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats